JULIE GARBUTT: Open Payments
NPI 1720077092 · PITTSBURGH, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$500 in 21 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $500
Food & beverage: $500
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 4 | $119 |
| ABBVIE INC. | 4 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $66 |
| Otsuka America Pharmaceutical, Inc. | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Alkermes, Inc. | 1 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Sage Therapeutics, LLC | 1 | $22 |
Products named: FANAPT, VRAYLAR, REXULTI, CAPLYTA, TRINTELLIX, Auvelity, ARISTADA, REJOYN.
Industry payments across PA — which companies pay providers there.
